Evidence map›Paper›PMID 36328340›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2023

Simultaneously ultrasensitive and quantitative detection of influenza A virus, SARS-CoV-2, and respiratory syncytial virus via multichannel magnetic SERS-based lateral flow immunoassay.

Zhenzhen Liu, Chongwen Wang, Shuai Zheng, Xingsheng Yang, Han Han, Yuwei Dai, Rui Xiao

Open access · greenAbstract read
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhenzhen LiuBeijing Institute of Microbiology and Epidemiology, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing 100850, PR China.
Chongwen WangBeijing Institute of Microbiology and Epidemiology, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing 100850, PR China.
Shuai ZhengBeijing Institute of Microbiology and Epidemiology, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing 100850, PR China.
Xingsheng YangBeijing Institute of Microbiology and Epidemiology, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing 100850, PR China.
Han HanBeijing Institute of Microbiology and Epidemiology, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing 100850, PR China.
Yuwei DaiBeijing Institute of Microbiology and Epidemiology, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing 100850, PR China.
Rui XiaoBeijing Institute of Microbiology and Epidemiology, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing 100850, PR China. Electronic address: ruixiao203@sina.com.
Institute of Microbiology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory viruses usually induced similar clinical symptoms at early infection. Herein, we presented a multichannel surface-enhanced Raman scattering-based lateral flow immunoassay (SERS-based LFA) using high-performance magnetic SERS tags for the simultaneous ultrasensitive detection of respiratory viruses, namely influenza A virus (H1N1), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and respiratory syncytial virus (RSV) in biological samples. As-prepared magnetic SERS tags can directly enrich and capture target viruses without pretreatment of samples, avoiding the interference of impurities in the samples as well as improving the sensitivity. With the capture-detection method, the detection limits of the proposed assay reached 85 copies mL

Indexed as

COVID-19Influenza A virusInfluenza A Virus, H1N1 SubtypeHumansMagnetic PhenomenaRespiratory Syncytial VirusesSARS-CoV-2Fe(3)O(4)@AuMagnetic tagsRespiratory virusesSERS-based lateral flow immunoassaySimultaneous detection

Identifiers

PMID36328340
PMCPMC9622431
OpenAlexW4308553482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.